HAL-2

General Information


DRACP ID  DRACP02009

Peptide Name   HAL-2

Sequence  GKWMSLLKHILK

Sequence Length  12

UniProt ID  Not available

PubChem CID  Not available

Origin  Halictines and their analogs

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=12±1 µM MTT assay 48 h 1
SW480 Colon adenocarcinoma Carcinoma IC50=35±3 µM MTT assay 48 h 1
CCRF-CEM Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50=34 µM MTT assay 48 h 1

Hemolytic Activity  Rat erythrocytes: IC50=78.1 μM

Normal (non-cancerous) Cytotoxicity  HUVEC: IC50=23±9 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02009

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C69H116N18O14S

Absent amino acids  ACDEFNPQRTVY

Common amino acids  KL

Mass  165025

Pl  11.1

Basic residues  4

Acidic residues  0

Hydrophobic residues  5

Net charge  4

Boman Index  59

Hydrophobicity  6.67

Aliphatic Index  130

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  500

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22100226

Title  Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells

Doi 10.1016/j.peptides.2011.11.002

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.